Imaavy — Initial Therapy
Covered when ALL of the following are met:
ALL of the following
Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Imaavy therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following
Positive serologic test for anti-acetylcholine receptor (AChR) antibodies.
Positive serologic test for anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy.
Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score ≥ 5 at initiation of therapy.
ONE of the following treatment-failure pathways
If anti-AChR antibody positive
History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
History of failure of at least one immunosuppressive therapy and required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control.
If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
Imaavy is dosed according to the U.S. Food and Drug Administration (FDA)-labeled dosing for gMG.
Prescribed by, or in consultation with, a neurologist.
Initial authorization will be for no more than 12 months.
Imaavy — Continuation Therapy
Covered when ALL of the following are met:
ALL of the following
Patient has previously been treated with Imaavy.
Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Imaavy.
Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Imaavy therapy will be considered treatment failure.
Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
Rystiggo — Initial Therapy
Covered when ALL of the following are met:
ALL of the following
Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Rystiggo therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
MGFA Clinical Classification of class II, III, or IV at initiation of therapy.
Rystiggo — Continuation Therapy
Covered when ALL of the following are met:
ALL of the following
Patient has previously been treated with Rystiggo.
Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of dose(s) of baseline IST prior to starting Rystiggo.
Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Rystiggo therapy will be considered treatment failure.
Patient is not receiving Rystiggo in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Imaavy (nipocalimab-aahu), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
Vyvgart/Vyvgart Hytrulo — Initial Therapy for gMG
Covered when ALL of the following are met:
ALL of the following
Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Vyvgart therapy.
Submission of medical records confirming that the patient has not failed a previous course of Vyvgart Hytrulo therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following antibody-status pathways
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
Vyvgart/Vyvgart Hytrulo — Continuation Therapy for gMG
Covered when ALL of the following are met:
ALL of the following
Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of dose(s) of baseline IST prior to starting Vyvgart or Vyvgart Hytrulo.
Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Vyvgart or Vyvgart Hytrulo therapy will be considered treatment failure.
gMG Continuation Therapy — Applicable Requirements
For continuation of gMG therapy with Vyvgart or Vyvgart Hytrulo, all applicable continuation requirements must be satisfied, including documented clinical response, appropriate dosing, prescriber qualifications, and the prohibition on combination use with specified therapies.
ALL of the following
Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
Documentation demonstrates improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline and reduction in signs and symptoms of myasthenia gravis.
Baseline IST is maintained, reduced, or discontinued; add-on IST, IST dose escalation, or additional rescue therapy to treat myasthenia gravis or exacerbation while on therapy is considered treatment failure.
Vyvgart or Vyvgart Hytrulo is not used in combination with a CD19-directed cytolytic antibody, complement inhibitor, FcRn blocker, or immune globulin.
Vyvgart Hytrulo — Initial Therapy for CIDP
Covered when ALL of the following are met:
ALL of the following
Patient has not failed a previous course of Vyvgart Hytrulo therapy.
Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), confirmed by progressive symptoms present for at least 2 months; symptomatic polyradiculoneuropathy indicated by progressive or relapsing motor or sensory impairment of more than one limb; and electrodiagnostic findings consistent with EFNS/PNS guidelines for definite CIDP.
At least one qualifying electrodiagnostic finding
Motor distal latency prolongation in 2 nerves.
Reduction of motor conduction velocity in 2 nerves.
Vyvgart Hytrulo — Continuation Therapy for CIDP
Covered when ALL of the following are met:
ALL of the following
Patient has previously been treated with Vyvgart Hytrulo.
Documentation of positive clinical response to therapy as measured by an objective scale (e.g., Rankin, Modified Rankin, or Medical Research Council [MRC] scale).
Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
Vyvgart Hytrulo is dosed according to the FDA-labeled dosing for CIDP.
Prescribed by, or in consultation with, a neurologist.
Generalized Myasthenia Gravis — Revised Antibody and Treatment-Failure Pathway
The revised generalized myasthenia gravis pathway recognizes the following antibody-status categories and corresponding treatment-failure requirements:
ALL of the following
Qualifying antibody status
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
Positive serologic test for anti-LRP4 antibodies.
Negative serologic tests for anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
Corresponding treatment-failure pathway
Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo must not be used in combination with one another or with other addressed FcRn blockers. These products must also not be used in combination with CD19-directed cytolytic antibodies, complement inhibitors, or immune globulin, as specified in the applicable product criteria.
Vyvgart or Vyvgart Hytrulo must not be used in combination with a CD19-directed cytolytic antibody, complement inhibitor, another FcRn blocker, or immune globulin.
U.S. Food and Drug Administration (FDA) approval alone is not a basis for coverage.